Cardinal Health
CAH
$225.38
-0.42%
Cardinal Health, Inc. is a leading pharmaceutical wholesaler and medical-surgical products distributor, operating primarily in the United States with additional presence in Europe and Asia. The company sources and distributes branded, generic, and specialty pharmaceuticals to retail pharmacies, hospital networks, and healthcare providers, and also supplies medical-surgical products and equipment to healthcare facilities. Alongside peers Cencora and McKesson, Cardinal Health controls well over 90% of the U.S. pharmaceutical wholesale market, making it a critical intermediary in the healthcare supply chain. The current investor narrative centers on the resilience of its generics business as a profit engine, with management guiding for 8-11% Pharma segment profit growth in fiscal 2027, while recent quarterly revenue misses have tempered enthusiasm despite strong earnings beats and raised profit outlooks. The stock is often framed as a value play within healthcare distribution, supported by a stable dividend and consistent cash generation.…
CAH
Cardinal Health
$225.38
Related headlines
Investment Opinion: Should I buy CAH Today?
Based on the synthesized data, Cardinal Health earns a Buy rating, though with moderate conviction. The core thesis is that CAH offers a compelling value proposition with a strong buy consensus (recommendation mean 1.5), a 20.2% upside to the average analyst target of $270.94, and a forward PE of 16.01x that is near the low end of its historical range. The company's resilient generics business, guided for 8-11% Pharma segment profit growth in fiscal 2027, and robust free cash flow of $4.39 billion support the bullish case.
Supporting evidence includes: (1) revenue growth of 11.05% year-over-year in Q3 2026, despite a sequential decline; (2) a low PS ratio of 0.22, which is near multi-year lows and suggests undervaluation relative to sales; (3) strong cash generation with $1.82 billion in operating cash flow in Q3 2026, comfortably covering dividends and capex; and (4) a dividend yield of 0.88% with a low payout ratio of 28.6%, providing income stability. The forward PE of 16.01x is in line with or slightly below the sector average, and the EV/EBITDA of 17.58x is moderate. However, the trailing PE of 32.68x and PEG of 2.68 indicate a premium on trailing earnings, and the negative equity and high debt-to-equity ratio of -3.45 are concerns.
The biggest risks that could invalidate the thesis are: (1) a continued revenue deceleration or miss, as seen in Q3 2026, which could pressure the stock; (2) margin compression below 4% gross margin, which would severely impact profitability; and (3) a valuation multiple contraction if earnings growth disappoints. The rating would upgrade to a strong buy if revenue growth reaccelerates above 12% and gross margins hold above 4.5%, or downgrade to a hold if revenue growth falls below 8% or operating margins drop below 0.7%. Relative to its history and peers, CAH appears fairly valued on forward earnings but slightly overvalued on trailing metrics. The stock is not a deep value play but offers a balanced risk-reward for income-oriented investors.
Sign up to view all
CAH 12-Month Price Forecast
Cardinal Health presents a balanced risk-reward profile with a bullish tilt, supported by a strong analyst consensus, attractive forward valuation, and resilient cash flows. The company's generics business remains a reliable profit engine, and management's guidance for 8-11% Pharma profit growth in fiscal 2027 provides visibility. However, the stock's premium trailing PE of 32.68x and recent revenue miss highlight the risk of multiple compression if growth disappoints. The low beta and stable dividend make it suitable for risk-averse investors, but the negative equity and thin margins are ongoing concerns. I would upgrade to high confidence if revenue growth reaccelerates above 12% and gross margins expand above 4.5%; I would downgrade to neutral if revenue growth falls below 8% or operating margins drop below 0.7%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $270.94 and implied upside of +20.2% versus the current price.
Average Target
$270.94
0 analysts
Implied Upside
+20.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$235 - $292
Analyst target range
Cardinal Health is covered by 16 analysts, with a consensus recommendation of "strong buy" (recommendation mean of 1.5). The average target price is $270.94, which implies an upside of approximately 20.2% from the current price of $225.38. The consensus leans bullish, with no sell ratings and a majority of buy or equivalent ratings. Recent institutional ratings show that firms like TD Cowen and B of A Securities have maintained Buy ratings, while JP Morgan remains Neutral, indicating a generally positive but not unanimous outlook. The estimated EPS average for the next fiscal year is $20.43, and revenue is expected to average $314.21 billion, supporting the optimistic targets.
The target price range spans from a low of $235.00 to a high of $292.00, representing a spread of about 24.3% around the average. The high target of $292.00 would require a forward PE of approximately 14.3x on the estimated EPS of $20.43, which is not overly aggressive and could be achieved through multiple expansion or better-than-expected earnings. The low target of $235.00 implies a forward PE of 11.5x, which may reflect concerns about margin compression or slower growth. The wide spread suggests moderate uncertainty, but the strong buy consensus and recent reiterations of Buy ratings indicate that analysts have confidence in the company's ability to deliver on its growth initiatives, particularly in the generics and specialty pharmaceutical businesses. The implied upside of 20.2% to the average target is substantial and may attract value-oriented investors.
Bulls vs Bears: CAH Investment Factors
The bull case for Cardinal Health rests on its strong analyst consensus, robust cash generation, and attractive forward valuation, while the bear case highlights thin margins, negative equity, and recent revenue misses. Currently, the bull evidence appears stronger: the 20.2% upside to the average analyst target, 8-11% guided Pharma profit growth, and $4.39 billion in free cash flow provide a solid foundation. However, the most critical tension is whether CAH can sustain its revenue growth trajectory and expand margins in a low-margin distribution business. If revenue growth decelerates further or margins compress, the premium trailing valuation could compress, outweighing the cash flow strengths. Conversely, if the generics business continues to deliver and revenue reaccelerates, the stock could re-rate toward the analyst targets.
Bullish
- Strong Buy Consensus with 20% Upside: All 16 covering analysts rate CAH a 'strong buy' (recommendation mean 1.5), with an average target price of $270.94 implying 20.2% upside from the current $225.38. Even the lowest target of $235.00 sits 4.3% above the current price, indicating that analysts see limited downside and substantial upside.
- Generics Profit Engine Guides 8-11% Growth: Management expects the Pharma segment to grow profit 8-11% in fiscal 2027, driven by generic and specialty pharmaceutical distribution. This guidance is supported by Q3 2026 revenue of $60.94 billion, up 11.05% year-over-year, demonstrating resilient demand despite a sequential revenue dip.
- Robust Free Cash Flow and Dividend Coverage: CAH generated $4.39 billion in trailing twelve-month free cash flow and $1.82 billion in operating cash flow in Q3 2026 alone. This comfortably covers the $120 million quarterly dividend and $146 million in capital expenditures, with a low payout ratio of 28.6% and a 0.88% dividend yield.
- Attractive Forward Valuation and Low Beta: The forward PE of 16.01x is near the low end of its historical range and below the trailing PE of 32.68x, implying expected earnings growth. The PS ratio of 0.22 is also near multi-year lows. Meanwhile, a beta of 0.519 means the stock is roughly 48% less volatile than the market, appealing to risk-averse investors.
Bearish
- Negative Equity and Leveraged Balance Sheet: CAH reports negative shareholders' equity, with a debt-to-equity ratio of -3.45 and a current ratio of 0.88, indicating potential liquidity tightness. The negative equity stems from aggressive share repurchases and debt, and while cash flow is strong, the leveraged balance sheet warrants close monitoring.
- Thin Margins Vulnerable to Cost Pressure: Gross margin was only 4.10% in Q3 2026, and operating margin was 0.84%, down from 1.08% in Q2 2026. Net margin stood at just 0.67%. Such razor-thin margins leave little room for error; any increase in drug costs, pricing pressure, or operational missteps could significantly impact profitability.
- Recent Revenue Miss and Sequential Decline: Q3 2026 revenue of $60.94 billion missed Wall Street expectations and declined sequentially from $65.44 billion in Q2 2026. This revenue shortfall overshadowed a strong earnings beat and raised profit outlook, causing the stock to drop sharply on April 30, 2026, highlighting sensitivity to top-line performance.
- Premium Trailing Valuation and High PEG: The trailing PE of 32.68x is above the midpoint of its historical range, and the PEG ratio of 2.68 suggests the stock may be overvalued relative to its expected growth rate. The negative price-to-book ratio of -19.45 makes book value comparison meaningless, and the stock trades at a premium on trailing earnings.
CAH Technical Analysis
Cardinal Health is in a sustained uptrend, with a 1-year price change of +50.21%, significantly outpacing the S&P 500's +15.01% over the same period. The current price of $225.38 sits at approximately 70.7% of its 52-week range (low of $145.87, high of $258.30), indicating that while the stock has pulled back from its highs, it remains in the upper half of its annual range. This positioning suggests that the long-term momentum is still positive, but the recent retreat from the high may signal a period of consolidation or profit-taking. The relative strength over 1 year is +35.20%, confirming persistent outperformance, yet the stock is not at an extreme overbought level given the distance from the 52-week high.
Short-term momentum has turned negative, with a 1-month price change of -4.03% and a 3-month change of +1.63%, diverging from the strong 1-year gain. This deceleration is further highlighted by the 6-month change of +8.44%, which is well below the 1-year performance, suggesting that the pace of gains has slowed considerably in recent months. The relative strength over 1 month is -3.07%, meaning the stock has underperformed the S&P 500 by that margin, and the 3-month relative strength is -0.37%, indicating a slight lag. This divergence could signal a temporary pullback within a longer-term uptrend or the early stages of a trend reversal, especially given the recent decline from the 52-week high of $258.30 to the current $225.38, a drop of about 12.7%.
Key technical levels to watch include support near the 52-week low of $145.87, though a more immediate support zone may be around the $200 psychological level, which also aligns with the stock's price action in May 2026. Resistance is established at the 52-week high of $258.30; a breakout above this level would confirm renewed bullish momentum and potentially attract further buying interest. Conversely, a breakdown below the $200 support could accelerate selling pressure and test the lower end of the range. The stock's beta of 0.519 indicates that it is significantly less volatile than the broader market—roughly 48% less volatile than SPY—which may appeal to risk-averse investors but also means it may lag in strong bull markets. The maximum drawdown of -20.61% over the past year reflects moderate risk, and the current price is about 12.7% below the 52-week high, suggesting a reasonable entry point for those bullish on the long-term trend.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$146-$258
Price range past year
Annual Return
+50.2%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | -4.0% | -0.5% |
| 3m | +1.6% | +2.3% |
| 6m | +8.4% | +16.6% |
| 1y | +50.2% | +14.8% |
| ytd | +9.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory remains solid, with the most recent quarter (Q3 2026, ended March 31, 2026) reporting revenue of $60.94 billion, representing a year-over-year growth rate of 11.05%. This growth is driven primarily by the Pharmaceutical segment, which generated $56.11 billion in revenue, while the GMPD segment contributed $3.15 billion and other operating segments added $1.71 billion. The multi-quarter trend shows revenue increasing from $60.16 billion in Q4 2025 to $64.01 billion in Q1 2026, $65.44 billion in Q2 2026, and then declining to $60.94 billion in Q3 2026, which is a sequential decrease but still a strong YoY improvement. The sequential decline may be due to seasonality or one-time factors, but the overall growth trend supports the investment case for continued demand in pharmaceutical distribution.
Profitability remains thin but stable, typical of the low-margin distribution industry. In Q3 2026, net income was $399 million, with a net margin of 0.67%, and gross margin stood at 4.10%. The gross margin has fluctuated slightly over recent quarters, from 3.38% in Q2 2026 to 4.10% in Q3 2026, but remains within the historical range of 3-4% for the company. Operating margin was 0.84% in Q3 2026, down from 1.08% in Q2 2026, but the company has demonstrated an ability to grow profits through cost control and generics optimization. The trailing twelve-month free cash flow is $4.39 billion, underscoring the company's cash-generating ability despite low margins.
The balance sheet shows a challenging equity position, with negative shareholders' equity due to aggressive share repurchases and debt, as evidenced by a debt-to-equity ratio of -3.45 and a current ratio of 0.88, indicating potential liquidity tightness. However, the company generates substantial operating cash flow—$1.82 billion in Q3 2026 alone—and free cash flow of $1.68 billion, which comfortably covers dividends ($120 million) and capital expenditures ($146 million). The return on equity is negative at -59.45%, but this is a function of the negative equity base rather than poor profitability; return on assets is positive at 3.72%. The company's cash conversion cycle is negative, reflecting efficient working capital management, and the interest coverage ratio of 5.04 times EBIT suggests the debt burden is manageable. Overall, Cardinal Health's financial health is sound from a cash flow perspective, but the leveraged balance sheet warrants monitoring.
Quarterly Revenue
$60.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
4.1%
Latest Quarter
Free Cash Flow
$4.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Since Cardinal Health reported positive net income (TTM net income of $1.56 billion), the PE ratio is the appropriate primary valuation metric. The trailing PE is 32.68x, while the forward PE is 16.01x, implying that the market expects significant earnings growth in the coming year. The large gap between trailing and forward PE suggests that analysts anticipate a substantial increase in EPS, likely driven by margin expansion and operational efficiencies. The PEG ratio of 2.68 indicates that the stock may be overvalued relative to its expected growth rate, but the forward PE of 16x is more reasonable and aligns with the company's projected EPS of $20.43 for the next fiscal year.
Compared to the broader healthcare distribution industry, Cardinal Health trades at a premium on some metrics and a discount on others. Its PS ratio of 0.22 is very low, reflecting the high-revenue, low-margin nature of the business, and is likely below the industry average. The EV/EBITDA of 17.58x is moderate, and the forward PE of 16.01x is in line with or slightly below the sector average, suggesting that the stock is not excessively expensive relative to peers. The price-to-book ratio is negative (-19.45) due to negative equity, making it not meaningful for comparison. Overall, the valuation appears reasonable given the company's stable cash flows and growth prospects, though the premium on trailing earnings reflects the cyclical low in profitability.
Historically, Cardinal Health's PE ratio has ranged from as low as 13.98x in March 2023 to over 100x during periods of depressed earnings. The current trailing PE of 32.68x is above the midpoint of its historical range, but the forward PE of 16.01x is near the lower end, suggesting that the market is pricing in a recovery in earnings. The PS ratio of 0.22 is near the low end of its historical range (0.30-0.81 over the past few years), which could indicate undervaluation relative to sales. However, the negative equity and high debt levels may justify a discount. The dividend yield of 0.88% is lower than the historical average of around 1.5-2%, reflecting the stock's price appreciation. In summary, the valuation is mixed: the forward earnings multiple is attractive, but the trailing metrics and negative book value suggest caution.
PE
32.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Cardinal Health faces significant financial and operational risks stemming from its highly leveraged balance sheet and razor-thin margins. The company reports negative shareholders' equity, with a debt-to-equity ratio of -3.45 and a current ratio of 0.88, indicating potential liquidity tightness. Although trailing twelve-month free cash flow of $4.39 billion comfortably covers the $120 million quarterly dividend and $146 million in capital expenditures, the negative equity base and high debt levels leave little cushion if cash flows deteriorate. Additionally, gross margin was only 4.10% in Q3 2026, and operating margin fell to 0.84% from 1.08% in Q2 2026, highlighting vulnerability to any cost inflation or pricing pressure. The company's profitability is highly sensitive to volume and generic drug pricing, and a revenue miss in Q3 2026 (revenue declined sequentially to $60.94 billion from $65.44 billion) underscores the risk of earnings volatility.
Market and competitive risks include valuation compression, as the trailing PE of 32.68x is above the midpoint of its historical range, and the PEG ratio of 2.68 suggests the stock may be overvalued relative to growth. The forward PE of 16.01x offers some support, but if earnings growth fails to materialize, the multiple could contract. Competition from peers like Cencora and McKesson is intense, and Cencora's recent raise of its 2026 EPS outlook due to specialty business strength highlights the competitive pressure in the specialty distribution space. Furthermore, CAH's low beta of 0.519 means it may lag in strong bull markets, and its recent underperformance (1-month relative strength of -3.07%) could continue if sector rotation favors higher-growth healthcare segments. Regulatory changes, such as drug pricing reforms or IRA impacts, could also pressure margins.
The worst-case scenario for CAH would involve a combination of revenue deceleration, margin compression, and multiple contraction. If revenue growth stalls or turns negative, and operating margins fall below 0.8%, earnings could decline sharply, leading to a sell-off. The stock could retest its 52-week low of $145.87, representing a 35.3% decline from the current price of $225.38. Even a drop to the analyst low target of $235.00 is unlikely to be the floor in a severe downturn; the 52-week low is a more realistic bear-case anchor. A broader market correction could exacerbate the decline given the stock's recent momentum loss. Investors could lose over a third of their capital in this adverse scenario, emphasizing the importance of risk management.
FAQ
The key risks for CAH include: (1) Financial risk from negative shareholders' equity and a debt-to-equity ratio of -3.45, which could limit financial flexibility; (2) Operational risk from razor-thin margins, with gross margin at 4.10% and operating margin at 0.84%, leaving little room for cost increases; (3) Market risk from valuation compression, as the trailing PE of 32.68x is above historical midpoints and could contract if growth slows; and (4) Competitive risk from peers like Cencora and McKesson, who are also strengthening their specialty businesses. Additionally, regulatory changes such as drug pricing reforms could pressure margins. The most severe risk is a revenue miss combined with margin compression, which could drive the stock toward its 52-week low of $145.87.
The 12-month forecast for CAH includes three scenarios: a bull case with 25% probability targeting $270.94-$292.00, a base case with 55% probability targeting $235.00-$270.94, and a bear case with 20% probability targeting $145.87-$235.00. The base case is most likely, assuming revenue growth stabilizes at 8-10% and margins remain around 4%, leading the stock to trade near the analyst average target of $270.94. The bull case requires successful execution on generics and margin expansion, while the bear case involves revenue deceleration and margin pressure. The key assumption behind the base case is that CAH meets its fiscal 2027 guidance of 8-11% Pharma segment profit growth.
CAH's valuation is mixed, with the forward PE of 16.01x suggesting it is fairly valued to slightly undervalued relative to its historical range and sector averages. The PS ratio of 0.22 is near multi-year lows, indicating potential undervaluation relative to sales. However, the trailing PE of 32.68x is above the midpoint of its historical range, and the PEG ratio of 2.68 suggests the stock may be overvalued relative to its expected growth rate. The negative price-to-book ratio of -19.45 makes book value comparison meaningless. The market appears to be pricing in a recovery in earnings, as evidenced by the large gap between trailing and forward PE. If the company delivers on its estimated EPS of $20.43, the stock could be undervalued; if growth disappoints, the premium trailing multiple could compress.
From a risk/reward perspective, CAH appears to be a good buy for value-oriented investors, with a strong buy consensus (recommendation mean 1.5) and an average target price of $270.94, implying 20.2% upside from the current $225.38. The forward PE of 16.01x is attractive relative to the trailing PE of 32.68x, suggesting expected earnings growth. However, the biggest downside risk is a revenue deceleration or margin compression, which could push the stock toward its 52-week low of $145.87, representing a 35% decline. The low beta of 0.519 and stable dividend yield of 0.88% make it suitable for conservative investors, but those seeking high growth may find better opportunities elsewhere. Overall, it is a good buy for income and value investors with a medium to long-term horizon, provided they can tolerate the thin margins and leveraged balance sheet.
CAH is more suitable for long-term investment, given its low beta of 0.519, stable dividend yield of 0.88%, and consistent free cash flow generation of $4.39 billion. The stock's defensive characteristics and strong buy consensus make it a good candidate for a buy-and-hold strategy, with a suggested minimum holding period of 12-18 months to ride out short-term volatility. Short-term trading is less attractive due to the recent negative momentum (1-month change of -4.03%) and the stock's low volatility, which limits quick gains. However, the upcoming earnings report could provide a short-term catalyst. Overall, long-term investors can benefit from the steady cash flows and potential upside to the analyst target of $270.94, while short-term traders may find better opportunities in higher-beta stocks.